Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6280646 | 0.86 | CYP3A4 (0.53) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL6281716 | 0.83 | CYP2D6 (0.46) | LMNATSHRCYP3A4CYP2D6 | |
| SCHEMBL6283413 | 0.79 | CYP3A4 (0.49) | MEN1KMT2ALMNATSHRCYP3A4 | |
| SCHEMBL7248964 | 0.77 | ALDH1A1 (0.53) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL7253156 | 0.76 | KMT2A (0.46) | SMN1; SMN2MEN1KMT2ALMNATSHR | |
| SCHEMBL7247504 | 0.73 | SCN4A (0.36) | MEN1KMT2ALMNATSHRCYP3A4 | |
| SCHEMBL7119899 | 0.69 | RXFP1 (0.46) | SMN1; SMN2MEN1KMT2ALMNAGAA | |
| SCHEMBL7807880 | 0.69 | ALDH1A1 (0.50) | MEN1KMT2ALMNAGAACYP3A4 | |
| SCHEMBL6286482 | 0.68 | CYP3A4 (0.64) | MEN1KMT2ALMNATSHRALOX15 | |
| SCHEMBL18486429 | 0.68 | POLB (0.58) | SMN1; SMN2MEN1KMT2ALMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | claimed |
| US-6552023-B2 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2003-04-22 | — | — | US | claimed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | claimed |
| US-6852723-B2 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. (US) | 2005-02-08 | — | — | US | disclosed |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | CV THERAPEUTICS, INC. | 2003-09-18 | — | — | US | disclosed |
| US-6552023-B2 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2003-04-22 | — | — | US | disclosed |
| EP-1259493-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | CV THERAPEUTICS, INC. | 2001-11-15 | — | — | US | disclosed |
| WO-2001062744-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS | CV THERAPEUTICS, INC. (US) | 2001-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010041704-A1 | N-(2,6-dimethylphenyl)-2-(4-(2-hydroxy-4-phenylbutyl) -piperazinyl)acetamide, for example; useful to protect skeletal muscles against damage from trauma or disease, treat shock, preserve donor tissue or organs; greater half-life | TNNC1, ATP2A1, ATP2A2 | SMN1; SMN2 133/4885MEN1 3990/4885KMT2A 3582/4885 |
| US-20030176440-A1 | Aralkyl substituted piperazine compounds | ATP2A1, ATP2A3, ATP2A2 | SMN1; SMN2 936/4885MEN1 4594/4885KMT2A 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.